- Home
- ARQQ vs CLLS Comparison
ARQQ vs CLLS Comparison
Compare ARQQ & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQQ | CLLS |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United Kingdom | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.7M | 374.2M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | ARQQ | CLLS |
|---|---|---|
| Price | $16.53 | $3.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $60.00 | $8.50 |
| AVG Volume (30 Days) | ★ 270.7K | 40.8K |
| Earning Date | 12-09-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $530,000.00 | ★ $82,551,000.00 |
| Revenue This Year | $381.13 | $32.58 |
| Revenue Next Year | $212.00 | $20.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $11.00 | $1.10 |
| 52 Week High | $62.00 | $5.48 |
Technical Indicators
Market Signals| Indicator | ARQQ | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 29.53 | 48.01 |
| Support Level | $15.89 | $3.44 |
| Resistance Level | $17.45 | $3.98 |
| Average True Range (ATR) | 1.57 | 0.21 |
| MACD | -0.23 | 0.02 |
| Stochastic Oscillator | 7.34 | 59.18 |
Price Performance
Historical ComparisonAbout ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.